Comparative Pharmacology
Head-to-head clinical analysis: KLEBCIL versus UTICILLIN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLEBCIL versus UTICILLIN VK.
KLEBCIL vs UTICILLIN VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Klebcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Uticillin VK (penicillin V potassium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) in the bacterial cytoplasmic membrane, thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
KLEBCIL (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) IV every 8 hours infused over 2 hours.
250-500 mg orally every 6-8 hours for 10 days for streptococcal pharyngitis; 250-500 mg orally every 6 hours for pneumococcal infections.
None Documented
None Documented
2-3 hours (prolonged to 30-60 hours in severe renal impairment; adjust dosing)
0.5-1.0 hour (prolonged in renal impairment; e.g., up to 10 hours in anuria)
Primarily renal (70-80% unchanged); minor biliary/fecal (15-20%)
Renal: 70-80% unchanged via tubular secretion and glomerular filtration; biliary/fecal: minor (about 10%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic